Last reviewed · How we verify
the first batch vaccine
the first batch vaccine is a Biologic drug developed by Beijing Chaoyang District Centre for Disease Control and Prevention. It is currently FDA-approved.
This is a vaccine formulation developed by Beijing Chaoyang District Centre for Disease Control and Prevention, but specific mechanistic details are not publicly available.
The first batch vaccine was developed by AstraZeneca as AZD1222, also known as VAC∆6 vaccine. It is a biological vaccine that induces an immune response, used to prevent conditions such as COVID-19, Smallpox, Monkeypox, Cowpox, and Vaccinia Virus Infection.
At a glance
| Generic name | the first batch vaccine |
|---|---|
| Sponsor | Beijing Chaoyang District Centre for Disease Control and Prevention |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Without access to detailed product information or clinical documentation, the precise mechanism of action cannot be reliably determined. The designation 'first batch vaccine' suggests it may be an early formulation of a vaccine candidate, but the target pathogen, immunological approach, and specific antigens involved are unknown.
Approved indications
Common side effects
Key clinical trials
- Clinical Trial for Batch Consistency of EV71 Vaccine (PHASE4)
- Phase II/III Randomized Clinical Trial of Booster Dose of COVID-19 (Recombinant, Inactivated) Vaccine (PHASE2, PHASE3)
- Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.
- Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine (PHASE4)
- Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain (PHASE4)
- Study on Immunogenicity, Reactogenicity and Safety of the VACΔ6 Vaccine in Volunteers Aged 18-60 Years (PHASE2, PHASE3)
- Non-Interventional Enhanced Active Surveillance Study of Adults Vaccinated With AZD1222
- Immunity and Safety of Inactivated Enterovirus 71 Vaccine Post-marketing Among Children Aged 6-35 Months in China (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- the first batch vaccine CI brief — competitive landscape report
- the first batch vaccine updates RSS · CI watch RSS
- Beijing Chaoyang District Centre for Disease Control and Prevention portfolio CI
Frequently asked questions about the first batch vaccine
What is the first batch vaccine?
How does the first batch vaccine work?
Who makes the first batch vaccine?
What development phase is the first batch vaccine in?
Related
- Manufacturer: Beijing Chaoyang District Centre for Disease Control and Prevention — full pipeline
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing